Investing

First Look Analysts Research Calls for Friday, February 24

Mario Tama / Getty Images News via Getty Images

This report was sent to Briefing.com subscribers earlier today. 

Upgrades:

> Century Aluminum (CENX) upgraded to Peer Perform from Underperform at Wolfe Research

> Esperion Therapeutics (ESPR) upgraded to Buy from Hold at Jefferies; tgt $12

> Grainger (GWW) upgraded to Sector Perform from Underperform at RBC Capital Mkts; tgt raised to $679

> LyondellBasell (LYB) upgraded to Outperform from Sector Perform at RBC Capital Mkts; tgt raised to $130

> NeoGenomics (NEO) upgraded to Buy from Hold at The Benchmark Company; tgt $20

> Youdao (DAO) upgraded to Buy from Hold at Jefferies; tgt raised to $10

Downgrades:

> C4 Therapeutics (CCCC) downgraded to Underweight from Neutral at JP Morgan; tgt lowered to $5

> CURO Group (CURO) downgraded to Underperform from Neutral at Credit Suisse; tgt lowered to $4

> Moderna (MRNA) downgraded to Underperform from Market Perform at SVB Securities; tgt lowered to $93

> Nektar Therapeutics (NKTR) downgraded to Underperform from Hold at Jefferies; tgt lowered to $1.50

> New York Mortgage Trust (NYMT) downgraded to Neutral from Buy at Ladenburg Thalmann

> OGE Energy (OGE) downgraded to Neutral from Buy at BofA Securities; tgt lowered to $39

Others:

> Biomea Fusion (BMEA) initiated with a Buy at Citigroup; tgt $20

> Erasca (ERAS) initiated with a Buy at Goldman; tgt $10

> KE Holdings (BEKE) initiated with a Buy at Daiwa Securities

Sponsored: Find a Qualified Financial Advisor

Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.